BonesLabsBlog
Back to all posts
Uncategorized

MOTS-C

MOTS-c: A Mitochondrial-Derived Peptide in Metabolic and Aging Research

Research summary. MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-residue peptide encoded within the mitochondrial 12S rRNA gene rather than the nuclear genome. It is the most extensively characterised member of the mitochondrial-derived peptide (MDP) family, alongside humanin and the SHLP series. MOTS-c has reframed parts of mitochondrial biology by demonstrating that the mitochondrial genome encodes circulating bioactive peptides that act as systemic metabolic signals rather than functioning solely within the organelle.

Molecular profile

  • Sequence: Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg (16 residues)
  • Molecular formula: C₁₀₁H₁₅₂N₂₈O₂₂S₂
  • Molecular weight: ~2174.6 g/mol
  • PubChem CID: 255386757
  • CAS Number: 1627580-64-6
  • Genomic origin: Encoded within the mitochondrial 12S rRNA gene (MT-RNR1)
  • Class: Mitochondrial-derived peptide (MDP)

Discovery and biological context

MOTS-c was first reported by the laboratory of Pinchas Cohen in 2015 [1], expanding the existing mitochondrial-derived peptide concept (humanin had been described in 2001). Its identification rested on the recognition that small open reading frames (sORFs) within mitochondrial RNAs could encode functional peptides. MOTS-c is detectable in plasma in mammals, and its circulating concentrations decline with age in published cohorts.

The peptide is unusual within mitochondrial biology because it is exported from the organelle, circulates systemically, and translocates to the nucleus under metabolic stress — behaviours not previously associated with mitochondrially encoded products.

Mechanism of action

MOTS-c is interpreted as a regulator of cellular metabolism with multiple coordinated effects:

  • AMPK pathway activation. A consistently reported activity of MOTS-c is activation of the AMP-activated protein kinase (AMPK) pathway, the master cellular energy-sensor. AMPK activation drives glucose uptake, fatty-acid oxidation, mitochondrial biogenesis, and broader catabolic adaptation.
  • Folate-cycle and one-carbon metabolism. Cohen-laboratory work has reported that MOTS-c suppresses the folate-methionine-purine biosynthesis cycle, increasing AICAR levels and contributing to AMPK activation through this metabolite-driven mechanism.
  • Insulin sensitisation. Research has reported that MOTS-c restores skeletal-muscle glucose uptake under insulin-resistant conditions in rodent models.
  • Nuclear translocation under metabolic stress. Research has reported that MOTS-c translocates to the nucleus under metabolic-stress conditions and modulates the expression of antioxidant-response genes, providing a direct mechanism by which a mitochondrially encoded peptide can shape the nuclear transcriptional response.

Preclinical research highlights

Skeletal-muscle glucose handling. Rodent studies have reported that MOTS-c administration increases skeletal-muscle glucose uptake, restores insulin sensitivity in aged or high-fat-diet mice, and increases AMPK activation in muscle tissue.

Body composition and adipose biology. Research has reported that MOTS-c administration prevents diet-induced obesity in mouse models, reduces white adipose tissue accumulation, and supports brown adipose tissue function.

Exercise capacity. Rodent studies have reported that MOTS-c administration improves running-wheel performance and treadmill-exercise endpoints, with effects amplified in aged animals. This finding is one of the most cited preclinical results for MOTS-c.

Bone and osteoporosis models. Research has reported that MOTS-c administration produces favourable bone-mineral-density outcomes in ovariectomy-induced osteoporosis models in rodents.

Aging biology. Plasma MOTS-c declines with age in published human and rodent cohorts, and exogenous administration has been associated with restoration of metabolic parameters toward younger-animal baselines. Lifespan and functional-aging endpoints have been reported in mouse studies, though the broader replication base remains modest.

Limitations and current uncertainty

Several caveats are important when reading the MOTS-c literature:

  • The peptide-pharmacokinetic profile of exogenous MOTS-c in vivo (clearance, bioavailability across delivery routes) is incompletely characterised in published work.
  • A defined cell-surface receptor for MOTS-c has not been firmly established; its mechanism of action appears to be heavily metabolite-mediated through AMPK.
  • Independent replication outside the originating laboratory is growing but remains less extensive than for the major incretin peptides.
  • Clinical-trial data in humans is limited; no late-stage trials of MOTS-c appear in major Western trial registries at the time of writing.

Current research status

MOTS-c is an investigational research peptide. It is not approved by the FDA for any indication. Research interest is concentrated in exercise physiology, metabolic disease, sarcopenia, and basic mitochondrial biology.

For research-supplier contexts, MOTS-c is supplied as a research-grade investigational peptide and is not intended for self-administration.

Key takeaways for researchers

  • MOTS-c is a 16-residue peptide encoded within the mitochondrial 12S rRNA gene, the most extensively characterised mitochondrial-derived peptide alongside humanin.
  • It is interpreted as an AMPK-pathway-activating metabolic regulator with effects on glucose handling, fatty-acid oxidation, and mitochondrial biogenesis.
  • Reported preclinical effects span skeletal-muscle insulin sensitivity, adipose biology, exercise capacity, bone density, and aspects of aging.
  • Plasma MOTS-c declines with age in published cohorts.
  • MOTS-c is not an FDA-approved drug and a defined cell-surface receptor remains incompletely characterised.

References

  1. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443–454.
  2. Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12:470.

This article is provided for educational and research purposes only. MOTS-c is a research peptide. It is not an approved drug or therapeutic agent and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.

MOTS-C | BonesLabs